Dramatic response to single‐agent atezolizumab in a patient with MSI‐H serous ovarian cancer. (18th January 2021)

• Record Type: Journal Article
• Authors: Ak, Naziye; Vatansever, Sezai
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 46:Number 6(2021)
• Page Start: 1787
• Page End: 1791
• Publication Date: 2021-01-18
• Subjects: atezolizumab -- immunotherapy -- microsatellite instability -- ovarian cancer -- PD‐L1; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.13364
• Languages: English
• ISSNs: 0269-4727

Abstract

Abstract: What is known and objective: Patients with ovarian cancer have not benefited substantially from immunotherapy. We report a case of ovarian cancer, however, that responded well to the programmed cell death‐ligand 1 inhibitor atezolizumab. Case summary: A 64‐year‐old woman with recurrent ovarian carcinoma, not responsive to platinum/taxane and bevacizumab therapy, was BRCA normal but showed loss of MLH1 and PMS2 proteins. She was treated with atezolizumab. After the third cycle, her CA 125 levels decreased to normal. Radiologic evaluation showed a near‐complete response. What is new and conclusion: Identifying response markers is important when choosing therapy for ovarian cancer patients. Abstract : In the last decade, immune checkpoint inhibitors (ICI) have shown impressive results in many solid tumours. However, patients with ovarian carcinoma have shown scanty but promising results in clinical trials. Determining the predictive biomarkers will help to identify the most appropriate patient subgroup to treat with ICI. Here, we report 64‐year‐old women with recurrent ovarian carcinoma, who have responded to atezolizumab, a programmed cell death‐ligand 1 inhibitor, even with a single dose. The radiologic assessment has shown a near‐complete response.